DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry

Recruiting

Conditions: Kidney Neoplasm

First Posted Date: 2015-01-27

Last Posted Date: 2024-07-09

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 600

Registration Number: NCT02346435

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

IFN-DLI for Relapsed Acute Leukemia After Allo-SCT

Early Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily

First Posted Date: 2015-01-06

Last Posted Date: 2020-04-21

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 16

Registration Number: NCT02331706

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Pembrolizumab

First Posted Date: 2014-12-12

Last Posted Date: 2025-01-22

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 51

Registration Number: NCT02316002

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy

Phase 2

Completed

Conditions: Patients With Stage IV or Recurrent Adenocarcinoma of the Lung

Interventions: Drug: Abraxane
Drug: Gemcitabine

First Posted Date: 2014-12-01

Last Posted Date: 2021-09-29

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 37

Registration Number: NCT02303977

RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers

Phase 1

Completed

Conditions: Metastatic Cancers

Interventions: Drug: Pembrolizumab
Radiation: Radiotherapy

First Posted Date: 2014-12-01

Last Posted Date: 2021-05-12

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 59

Registration Number: NCT02303990

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Healthy Human Control Blood Collection for Validation of Biomarker Assay

Active, not recruiting

Conditions: Healthy

First Posted Date: 2014-11-27

Last Posted Date: 2025-01-28

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 43

Registration Number: NCT02302885

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.

Not Applicable

Completed

Conditions: Oropharyngeal Cancer
Squamous Cell Carcinoma to the Head and Neck

Interventions: Drug: Lyrica 300 mg
Drug: Placebo

First Posted Date: 2014-10-29

Last Posted Date: 2019-11-21

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT02277548

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1

Withdrawn

Conditions: Ovarian, Fallopian Tube and Peritoneal Cancer

First Posted Date: 2014-10-29

Last Posted Date: 2018-09-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT02277392

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Phase 1

Completed

Conditions: Advanced BRAF Mutant Melanoma

Interventions: Drug: Trametinib 2 mg daily
Drug: hydroxychloroquine (HCQ)
Drug: dabrafenib 150 mg orally twice a day

First Posted Date: 2014-10-06

Last Posted Date: 2022-01-20

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 50

Registration Number: NCT02257424

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 1 locations

Exercise and Colon Cancer

Not Applicable

Completed

Conditions: Stage III Colon Cancer
Stage II Colon Cancer

Interventions: Other: Exercise

First Posted Date: 2014-09-26

Last Posted Date: 2020-04-09

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 44

Registration Number: NCT02250053

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy